BOEHRINGER INGELHEIM PHARMA TO ACQUIRE ZANTAC FROM JOHNSON & JOHNSON AND PFIZER CONSUMER HEALTHCARE BUSINESS

Boehringer Ingelheim Pharmaceuticals Inc. said Thursday it has entered into an agreement with Johnson & Johnson and Pfizer Inc. to acquire the U.S. rights to the over-the-counter Zantac product line for $509.5 million in cash. Trading Markets (http://www.tradingmarkets.com/.site/news/BREAKING%20NEWS/455932/)